Grant: Proof of Principle Program - Phase I
McGill University
$150,000.00
Smart Ultrasonic Hydrogel Sensors for Point of Care Analysis
EF 2008-09
Résumé
A team of scientists at McGill University has discovered that ultrasound can be used as a detection signal in combination with uniquely derivatized antibodies (immunoassay) to measure the concentration of substances in biological fluids. Currently used immunoassays employ other detection mechanisms such as radioactivity, enzyme activity, fluorescence or luminescence. Preliminary results indicate that the new method is at least as sensitive and reproducible as the conventional approaches, but is much simpler, faster and cheaper. Because of this, it is expected that the method could be used in hospitals as a Point of Care procedure for diagnosis. This means that the patient's sample could be immediately analyzed in the hospital ward rather than sending it to a central lab. Another advantage is the possibility of being able to simultaneously measure several different substances in the same sample. The method has been successfully applied to the measurement of a protein. Results obtained thus far have been protected by a patent application, now at the international stage.
The team is now planning to adapt the method to the measurement of small molecules, which could then be used for therapeutic drug monitoring, detection of drugs of abuse, and analysis of certain hormones. They will also determine if the method can be used on whole blood. The third aspect of the project is to design and assemble a simple ultrasound device dedicated to this new application.
Immunoassay is widely used for diagnostic purposes in cancer, endocrinology, infectious diseases and other areas. The total annual world market for reagents and devices is several billion dollars. The new technology being developed at McGill will improve health care by providing a new in vitro diagnostic technology that is faster and more economical than existing approaches
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
174439
Name
Burns David H
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Smart Ultrasonic Hydrogel Sensors for Point of Care Analysis
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Abstract
A team of scientists at McGill University has discovered that ultrasound can be used as a detection signal in combination with uniquely derivatized antibodies (immunoassay) to measure the concentration of substances in biological fluids. Currently used immunoassays employ other detection mechanisms such as radioactivity, enzyme activity, fluorescence or luminescence. Preliminary results indicate that the new method is at least as sensitive and reproducible as the conventional approaches, but is much simpler, faster and cheaper. Because of this, it is expected that the method could be used in hospitals as a Point of Care procedure for diagnosis. This means that the patient's sample could be immediately analyzed in the hospital ward rather than sending it to a central lab. Another advantage is the possibility of being able to simultaneously measure several different substances in the same sample. The method has been successfully applied to the measurement of a protein. Results obtained thus far have been protected by a patent application, now at the international stage.
The team is now planning to adapt the method to the measurement of small molecules, which could then be used for therapeutic drug monitoring, detection of drugs of abuse, and analysis of certain hormones. They will also determine if the method can be used on whole blood. The third aspect of the project is to design and assemble a simple ultrasound device dedicated to this new application.
Immunoassay is widely used for diagnostic purposes in cancer, endocrinology, infectious diseases and other areas. The total annual world market for reagents and devices is several billion dollars. The new technology being developed at McGill will improve health care by providing a new in vitro diagnostic technology that is faster and more economical than existing approaches
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Burns, David H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~